{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:46:00Z","timestamp":1792010760841,"version":"4.4.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Transl Gastroenterol","Clinical and Translational Gastroenterology"],"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Anti-integrin \u03b1v\u03b26 (anti-\u03b1v\u03b26) autoantibodies serve as a diagnostic biomarker and are associated with poor prognosis in ulcerative colitis (UC). We aimed to investigate whether anti-\u03b1v\u03b26 autoantibody levels predict treatment outcomes of advanced therapies in patients with moderately to severely active UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Anti-\u03b1v\u03b26 autoantibody levels were measured using prospectively collected serum samples at the initiation of advanced therapies. The primary outcome was treatment persistence up to 1 year; secondary outcomes included clinical remission rates at weeks 2, 6, 14, 24, and 48, comparing low-level and high-level groups stratified by an optimal cutoff from receiver operating characteristic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      A total of 144 patients were analyzed (121 [84.0%] with extensive colitis and 87 [60.4%] with prior exposure to advanced therapies). The median observation period was 10 months, and treatment discontinuation occurred in 70 patients (48.6%). Treatment persistence was significantly higher in the low-level group (log-rank test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), and multivariable Cox analysis identified low antibody levels as the only independent predictor (hazard ratio, 1.90; 95% CI, 1.09\u20133.32). Clinical remission rates were consistently higher in the low-level group throughout all time points, with the greatest difference at week 6 (47.5% vs 20.0%; \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). Low antibody levels remained an independent predictor of remission at all time points.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Anti-\u03b1v\u03b26 autoantibodies predicted both treatment persistence and clinical remission after advanced therapies, highlighting their potential as a predictive biomarker in patients with active UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.14309\/ctg.0000000000000990","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:00:34Z","timestamp":1770123634000},"page":"e00990","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Integrin \u03b1v\u03b26 Autoantibodies Predict Response and Treatment Persistence to Advanced Therapies in Ulcerative Colitis"],"prefix":"10.14309","volume":"17","author":[{"given":"Shunsuke","family":"Shibui","sequence":"first","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;"},{"name":"Department of Gastroenterology, Yokohama City University, Graduate School of Medicine, Yokohama, Kanagawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Asonuma","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuronuma","sequence":"additional","affiliation":[{"name":"Biomedical Laboratory, Department of Research, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Okabayashi","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanade","family":"Serizawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Umeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Sagami","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Berman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Affiliated with the Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Biomedical Laboratory, Department of Research, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsan","family":"Maharshak","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Affiliated with the Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama City University, Graduate School of Medicine, Yokohama, Kanagawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3]]},"reference":[{"issue":"1","key":"R1-20261014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"R2-20261014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R3-20261014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohn's Colitis"},{"issue":"4","key":"R4-20261014","doi-asserted-by":"crossref","first-page":"102317","DOI":"10.1016\/j.clinre.2024.102317","article-title":"The diagnostic performance of serum \u03b1v\u03b26 autoantibodies for ulcerative colitis: A systematic review and meta-analysis","volume":"48","author":"Yang","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"R5-20261014","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00535-025-02263-7","article-title":"Autoantibodies against endothelial protein C receptor and integrin \u03b1v\u03b26 predict the development of ulcerative colitis","volume":"60","author":"Sawahashi","year":"2025","journal-title":"J Gastroenterol"},{"issue":"1","key":"R6-20261014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00535-024-02176-x","article-title":"Anti-integrin \u03b1v\u03b26 antibody as a biomarker for diagnosing ulcerative colitis: A nationwide multicenter validation study","volume":"60","author":"Okabe","year":"2024","journal-title":"J Gastroenterol"},{"issue":"7","key":"R7-20261014","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","article-title":"Identification of an anti\u2013integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis","volume":"160","author":"Kuwada","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"R8-20261014","doi-asserted-by":"crossref","first-page":"jjaf062","DOI":"10.1093\/ecco-jcc\/jjaf062","article-title":"Anti-integrin \u03b1v\u03b26 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype","volume":"19","author":"Pertsinidou","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"4","key":"R9-20261014","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"R10-20261014","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol"},{"issue":"26","key":"R11-20261014","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"R12-20261014","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/apt.13408","article-title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","volume":"42","author":"Jairath","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"26","key":"R13-20261014","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"New Engl J Med"},{"issue":"Suppl A","key":"R14-20261014","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal world congress of gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"R16-20261014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2036.2000.00705.x","article-title":"Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis","volume":"14","author":"Carbonnel","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"R17-20261014","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"issue":"1","key":"R18-20261014","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"R19-20261014","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/ibd\/izab032","article-title":"Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease","volume":"27","author":"Verstockt","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"R20-20261014","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"R21-20261014","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"R22-20261014","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/ecco-jcc\/jjad170","article-title":"Baseline TREM-1 whole blood gene expression does not predict response to adalimumab treatment in patients with ulcerative colitis or crohn's disease in the SERENE studies","volume":"18","author":"Verstockt","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R23-20261014","doi-asserted-by":"crossref","first-page":"17562848241258372","DOI":"10.1177\/17562848241258372","article-title":"Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis","volume":"17","author":"Gros","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"R24-20261014","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"R25-20261014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","article-title":"Long-term outcome after infliximab for refractory ulcerative colitis","volume":"2","author":"Ferrante","year":"2008","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"R26-20261014","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"R27-20261014","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S2468-1253(23)00154-1","article-title":"Difficult-to-treat inflammatory bowel disease: Results from an international consensus meeting","volume":"8","author":"Parigi","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"R28-20261014","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000001033","article-title":"A practical guide to combination advanced therapy in inflammatory bowel disease","volume":"40","author":"Ray","year":"2024","journal-title":"Curr Opin Gastroenterol"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.14309\/ctg.0000000000000990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:00:54Z","timestamp":1792008054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.14309\/ctg.0000000000000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.14309\/ctg.0000000000000990","relation":{},"ISSN":["2155-384X","2155-384X"],"issn-type":[{"value":"2155-384X","type":"electronic"},{"value":"2155-384X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2026-01-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}